Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform

Abigail E. Besemer, You Ming Yang, Joseph J. Grudzinski, Lance T. Hall, Bryan P. Bednarz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000 g. The majority of the S-values and SAFs calculated in the Zubal Phantom were within 5% of the previously published values with the exception of a few 10 keV photon SAFs that agreed within 10%, and one value within 16%. The S-values calculated in the spherical tumor phantoms agreed within 2% for 177Lu, 131I, 125I, 18F, and 64Cu, within 3.5% for 211At and 213Bi, within 6.5% for 153Sm, 111In, 89Zr, and 223Ra, and within 9% for 90Y, 68Ga, and 124I. In conclusion, RAPID is capable of calculating accurate internal dosimetry at the voxel-level for a wide variety of radionuclides and could be a useful tool for calculating patient-specific 3D dose distributions.

Original languageEnglish (US)
Pages (from-to)155-165
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Volume33
Issue number4
DOIs
StatePublished - May 2018

Fingerprint

Radiopharmaceuticals
Photons
Radioisotopes
Neoplasms
Electrons
Single Photon Emission Computed Tomography Computed Tomography

Keywords

  • Internal dosimetry
  • Monte Carlo
  • radiopharmaceuticals
  • targeted radionuclide therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Development and Validation of RAPID : A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform. / Besemer, Abigail E.; Yang, You Ming; Grudzinski, Joseph J.; Hall, Lance T.; Bednarz, Bryan P.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 33, No. 4, 05.2018, p. 155-165.

Research output: Contribution to journalArticle

Besemer, Abigail E. ; Yang, You Ming ; Grudzinski, Joseph J. ; Hall, Lance T. ; Bednarz, Bryan P. / Development and Validation of RAPID : A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform. In: Cancer Biotherapy and Radiopharmaceuticals. 2018 ; Vol. 33, No. 4. pp. 155-165.
@article{b658b59b1bb3404b979e294eed4c5f22,
title = "Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform",
abstract = "This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000 g. The majority of the S-values and SAFs calculated in the Zubal Phantom were within 5{\%} of the previously published values with the exception of a few 10 keV photon SAFs that agreed within 10{\%}, and one value within 16{\%}. The S-values calculated in the spherical tumor phantoms agreed within 2{\%} for 177Lu, 131I, 125I, 18F, and 64Cu, within 3.5{\%} for 211At and 213Bi, within 6.5{\%} for 153Sm, 111In, 89Zr, and 223Ra, and within 9{\%} for 90Y, 68Ga, and 124I. In conclusion, RAPID is capable of calculating accurate internal dosimetry at the voxel-level for a wide variety of radionuclides and could be a useful tool for calculating patient-specific 3D dose distributions.",
keywords = "Internal dosimetry, Monte Carlo, radiopharmaceuticals, targeted radionuclide therapy",
author = "Besemer, {Abigail E.} and Yang, {You Ming} and Grudzinski, {Joseph J.} and Hall, {Lance T.} and Bednarz, {Bryan P.}",
year = "2018",
month = "5",
doi = "10.1089/cbr.2018.2451",
language = "English (US)",
volume = "33",
pages = "155--165",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Development and Validation of RAPID

T2 - A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform

AU - Besemer, Abigail E.

AU - Yang, You Ming

AU - Grudzinski, Joseph J.

AU - Hall, Lance T.

AU - Bednarz, Bryan P.

PY - 2018/5

Y1 - 2018/5

N2 - This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000 g. The majority of the S-values and SAFs calculated in the Zubal Phantom were within 5% of the previously published values with the exception of a few 10 keV photon SAFs that agreed within 10%, and one value within 16%. The S-values calculated in the spherical tumor phantoms agreed within 2% for 177Lu, 131I, 125I, 18F, and 64Cu, within 3.5% for 211At and 213Bi, within 6.5% for 153Sm, 111In, 89Zr, and 223Ra, and within 9% for 90Y, 68Ga, and 124I. In conclusion, RAPID is capable of calculating accurate internal dosimetry at the voxel-level for a wide variety of radionuclides and could be a useful tool for calculating patient-specific 3D dose distributions.

AB - This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000 g. The majority of the S-values and SAFs calculated in the Zubal Phantom were within 5% of the previously published values with the exception of a few 10 keV photon SAFs that agreed within 10%, and one value within 16%. The S-values calculated in the spherical tumor phantoms agreed within 2% for 177Lu, 131I, 125I, 18F, and 64Cu, within 3.5% for 211At and 213Bi, within 6.5% for 153Sm, 111In, 89Zr, and 223Ra, and within 9% for 90Y, 68Ga, and 124I. In conclusion, RAPID is capable of calculating accurate internal dosimetry at the voxel-level for a wide variety of radionuclides and could be a useful tool for calculating patient-specific 3D dose distributions.

KW - Internal dosimetry

KW - Monte Carlo

KW - radiopharmaceuticals

KW - targeted radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=85047106367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047106367&partnerID=8YFLogxK

U2 - 10.1089/cbr.2018.2451

DO - 10.1089/cbr.2018.2451

M3 - Article

C2 - 29694246

AN - SCOPUS:85047106367

VL - 33

SP - 155

EP - 165

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -